Jazz Pharmaceuticals plc (JAZZ)
OrangeHealth Care · As of 17 July 2026
Price chart — 52 weeks
OakBag’s model puts the fair value of Jazz Pharmaceuticals plc (JAZZ) at about $307.13, against a recent price of $247.53 — a margin of safety of +19%. On that basis the traffic light is set so it looks fairly valued. The estimate blends up to 1 independent valuation methods and is benchmarked against other Health Care names. It is a model estimate for research, not a price target or a recommendation.
Fair value vs. price
- Current price
- $247.53
- Estimated fair value
- $307.13
- Margin of safety
- +19%
How the fair value is built
Why not green?
- The company is running an operating loss, so the screen will not flag a money-losing business as a buy.
- Only one valuation method applies to this business — too thin to flag as a buy on its own.
Knock-out safety checks passed
- Bankruptcy risk (Altman Z″)
- Negative equity
- Excessive leverage
- Illiquid
- Penny / micro-cap
- Stale fundamentals
- Piotroski F-score
- 4 / 9
- Beneish M-score
- -2.98
Quality & factor profile
See the full analysis
Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for JAZZ and 1,850+ other stocks.
No credit card · just an email
Frequently asked questions
Is Jazz Pharmaceuticals (JAZZ) undervalued?
On OakBag’s model, Jazz Pharmaceuticals plc looks fairly valued: the estimated fair value is $307.13 versus a recent price of $247.53, a margin of safety of +19%. This is a model estimate, not investment advice.
What is JAZZ’s fair value estimate?
OakBag estimates Jazz Pharmaceuticals plc’s fair value at about $307.13, blending up to 1 methods — peer P/E, price-to-book, peer EV/EBITDA, a machine-learning valuation and a cash-flow DCF — clipped to a sensible band and taken at the median.
What is margin of safety?
Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. Here it is +19%. A positive number means the model sees the stock as cheap; OakBag only turns a stock green above +15%.
Does a green verdict mean I should buy JAZZ?
No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.
Other Health Care stocks
An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.